Skip to main
  1. Stocks
  2. Cytokinetics
  3. Forecast
CYTK

Cytokinetics (CYTK) Stock Forecast & Price Target

Cytokinetics (CYTK) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cytokinetics is supported by a strong commercial launch for MYQORZO, with U.S. revenue of $43.1M in 3Q26, about 2,800 patients dispensed therapy, and >80% of prescriptions paid, while market share approached 45% and commercial coverage exceeded 60%. Its outlook is further strengthened by a large, underpenetrated HCM market, differentiated clinical data in both oHCM and nHCM, and a broad label expansion opportunity, including MAPLE-HCM with PDUFA set for November 14, 2026 and an nHCM sNDA expected in 4Q26. The company also has expanding international momentum, with approvals in China, the U.S., the EU, the UK, Germany, and Canada, and its pipeline value is anchored by aficamten, which represents 76% of the valuation.

Bears say

Cytokinetics is viewed negatively because its lead asset, aficamten (Myqorzo), faces meaningful clinical and regulatory risk in nHCM, while omecamtiv mecarbil or ulacamten could still fail in ongoing studies. Safety data already show LVEF <50% in 10.5% of aficamten patients versus 0.8% on placebo, with two serious HF events tied to reduced LVEF and ten additional serious HF events, underscoring a narrow therapeutic window. Commercially, even if approved, uptake could be constrained by reimbursement hurdles in Europe or China, restrictive U.S. payer coverage, and a lack of clear differentiation versus mavacamten, limiting meaningful market share.

Cytokinetics (CYTK) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cytokinetics and is not a guaranteed prediction by Public.com or investment advice.

Cytokinetics (CYTK) Analyst Forecast & Price Prediction

Get the latest Cytokinetics (CYTK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cytokinetics (CYTK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cytokinetics (CYTK) Forecast

Analysts have given Cytokinetics (CYTK) a Buy based on their latest research and market trends.

According to 16 analysts, Cytokinetics (CYTK) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cytokinetics (CYTK)


Cytokinetics (CYTK) Analyst Forecast & Price Prediction

Get the latest Cytokinetics (CYTK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cytokinetics (CYTK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CYTK stock data and trends